| Drug General Information |
| Drug ID |
D0C7JC
|
| Former ID |
DNC004858
|
| Drug Name |
5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H8N2OS
|
| Canonical SMILES |
C1=CC(=CN=C1)C2=CC=C(S2)C=NO
|
| InChI |
1S/C10H8N2OS/c13-12-7-9-3-4-10(14-9)8-2-1-5-11-6-8/h1-7,13H/b12-7+
|
| InChIKey |
HRTKQHILWNVFIX-KPKJPENVSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tamoxifen metabolism
|
|
Tryptophan metabolism
|
|
Oxidation by Cytochrome P450
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Vitamin D Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | J Med Chem. 2005 Jan 13;48(1):224-39.5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. |
|---|
